Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00947011 · ClinicalTrials.gov registry record · Phase 2
Dipeptidyl Peptidase-4 Inhibition on Glucagon-like Peptide-1 (GLP-1)
A Phase 2 study, sponsored by Johns Hopkins University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT00947011: Clinical Trial Phase 2 study, sponsored by Johns Hopkins University.
NCT00947011 is a Phase 2 study that was terminated before completion, run by Johns Hopkins University. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00947011, a Phase 2 study, was terminated before completion, sponsored by Johns Hopkins University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
This research is being done to evaluate the effect of glucagon-like peptide-1 (GLP-1, a naturally occurring hormone) on insulin release and to examine whether there is extra insulin release when GLP-1 is not allowed to be rapidly inactivated.
Interventions
- DRUG Placebo
- DRUG Januvia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2009-03 |
| Est. Completion | 2010-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00947011
The ClinicalTrials.gov registry entry for NCT00947011 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00947011 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00947011 about?
NCT00947011 is a clinical study titled "Dipeptidyl Peptidase-4 Inhibition on Glucagon-like Peptide-1 (GLP-1)". This research is being done to evaluate the effect of glucagon-like peptide-1 (GLP-1, a naturally occurring hormone) on insulin release and to examine whether there is extra insulin release when GLP-1 is not allowed to be rapidly inactivated.
What is the current status of trial NCT00947011?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2009-03. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00947011?
The interventions under investigation include: Placebo (DRUG), Januvia (DRUG).
Who is sponsoring clinical trial NCT00947011?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.